CCS1477 is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer. CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.
Testimonial
“Interactions with Midven have always been open and straightforward. Investments have always been clearly structured and compatible with others, including high net worths, Institutional and corporate investors.”
Will West, Cellcentric
Word Description
“Interactions with Midven have always been open and straightforward. Investments have always been clearly structured and compatible with others, including high net worths, Institutional and corporate investors.”
Will West, Cellcentric